# A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD

> **NCT03062579** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fu-Dong Shi** · enrollment: 10 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorders
- Neuromyelitis Optica
- Devic's Disease

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03062579
- **Lead sponsor:** Fu-Dong Shi
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-01
- **Primary completion:** 2018-02-15
- **Final completion:** 2018-05-15
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03062579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03062579, "A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03062579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*